ALPCO’s Pancreatic Elastase Test supports accurate detection of EPI with easy sample collection, no dietary restrictions, and reliable performance.
ALPCO’s automated turbidimetric solution for calprotectin testing offers enhanced efficiency without compromising clinical sensitivity or specificity. Clinicians can prioritize endoscopic evaluation for the patients that need it most and quickly put IBS patients on the right treatment path.
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.
In an effort to improve patient care, an increasing number of gastroenterologists are using fecal calprotectin levels as a first step in the diagnosis of IBD versus IBS. ALPCO tests enable clinicians to accurately assess patients via calprotectin and quickly start patients on the right treatment path.
60 to 70 million Americans are affected by gastrointestinal (GI) diseases and disorders each year. The estimated annual U.S. cost associated with GI disorders is over 140 billion dollars. Gl diseases and disorders can have a significant impact on quality of life, often contributing to anxiety and depression.2 The ongoing challenge relates to overlapping symptoms and the compl...
Digestive Diseases Affect More than 70 Million Americans Each Year. The estimated annual cost of GI disorders is $135 billion, with patients reporting a higher incidence of depression and absenteeism. Comparatively, approximately 34 million Americans have diabetes.
